Valeant has rapidly expanded its neurological business over the past three years through the acquisitions of
several products. These products provide hope for relief to patients suffering from debilitating diseases
such as Parkinson's disease, epilepsy, migraine, and Myasthenia Gravis.
With more than one million people in the United States diagnosed with Parkinson's disease, and 60,000 new
cases diagnosed each year, Valeant remains committed to the Parkinson's disease community. One of Valeant's
products that provides therapies that fill this tremendous unmet medical
need is Zelapar®. Zelapar uses a
novel oral delivery system called Zydis Technology, which allows the tablets to dissolve within seconds in
the mouth resulting in once-daily dosing and a more active drug at a lower dose.
Approximately 2.7 million people in the United States suffer from epilepsy and 70 percent of those patients
may experience breakthrough seizures. Valeant provides epilepsy patients with Diastat®
AcuDialTM (diazepam
rectal gel). Diastat AcuDial is the only FDA-approved at-home acute treatment for breakthrough seizures.
Its effective, safe, and easy application provides children with breakthrough seizures an option for relief.
Valeant is continuing to explore potential avenues for relief from seizures. retigabine is the first
selective neuronal potassium channel opener in Phase 3 development as a novel adjunctive treatment for
partial onset seizures in patients with epilepsy.
Valeant's neurological portfolio offers many other products to assist patients with these conditions. Please
view our portfolio to further explore the
available options.
Zelapar Important Safety information
Zelapar is a special formulation of the drug selegiline that adds more active hours for patients with
Parkinson's disease (PD). Doctors may recommend adding Zelapar to levodopa/carbidopa treatment when patients
are experiencing a reduced response to this therapy.
Do not take Zelapar if you are allergic to selegiline or any of the other ingredients in Zelapar. Zelapar
should not be taken with certain medications. Discuss any medicine you are taking with your doctor. Zelapar
should not be taken with meperedine (DEMEROL®) or other opiods. Rare cases of high blood pressure have
been associated with taking conventional forms of selegiline with foods containing tyramine. Zelapar may
cause you to have low blood pressure when you stand (this is more common in older patients than in younger
ones). If you are pregnant, you must speak to your doctor about whether to take Zelapar. (Zelapar should be
used during pregnancy only if the potential benefit to the mother justifies the potential risk to the
fetus.) Do not take more than 2 tablets (2.5 mg) a day.
Zelapar was very well tolerated in clinical trials. The most commonly reported side effects were dizziness,
nausea, pain, headache, trouble sleeping, runny nose, involuntary movements, back pain, skin disorders,
mouth inflammation, and upper stomach pain. In addition, 5.2% of patients discontinued Zelapar therapy due
to side effects (vs. 1% with placebo).
You may need your levodopa dose reduced after starting Zelapar therapy. Be sure to speak with your doctor if
you experience any side effects.
For complete Prescribing Information please visit www.zelapar.com
Diastat AcuDial Important Safety information
DIASTAT AcuDial (diazepam rectal gel) is a gel formulation of diazepam intended for rectal
administration in the management of selected, refractory patients with epilepsy, on stable regimens of AEDs,
who require intermittent use of diazepam to control bouts of increased seizure activity for patients 2 years
and older.
In clinical trials with DIASTAT, the most frequent side effect was sleepiness (23%). Less frequent
adverse events reported were dizziness, headache, pain, vasodilatation, diarrhea, ataxia, euphoria,
incoordination, asthma, rash, abdominal pain, nervousness and rhinitis (1%-5%).
For complete Prescribing Information please visit www.diastat.com
|
